Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brustel is a combination analgesic and antipyretic medication containing ibuprofen and paracetamol. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in pain, inflammation, and fever. Paracetamol (acetaminophen) provides complementary analgesic and antipyretic effects, primarily through the central nervous system. The combination is indicated for the symptomatic treatment of mild to moderate pain, such as headache, toothache, musculoskeletal pain, and dysmenorrhea, as well as for the reduction of fever. It is manufactured by the Russian pharmaceutical company Biosintez.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + paracetamol.